LipitenCliDec Study – the profile of patients with uncontrolled arterial hypertension and/or dyslipidemia in primary care in the Czech Republic: the 2nd phase results

Authors: Martin Šatný 1;  Eva Tůmová 1;  Michal Vrablík 1;  Jana Mašková 2;  Jiří Laštůvka 3
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze 1;  NEOX s. r. o, Clinical Research, Praha 2;  Interní oddělení, Masarykova nemocnice v Ústí nad Labem, o. z, Krajská zdravotní, a. s. 3
Published in: AtheroRev 2020; 5(2): 117-123


In the previous issue of this journal – AtheroReview 2020; 5(1): 47–52 – the baseline data of the LipitenCliDec study (ie, the results of the first phase) were published. Study aim was to map the characteristics of patients with decompensated arterial hypertension (AH) and / or dyslipidemia (DLP), to identify possible explanatory causes of poor control of these risk factors (RF), to evaluate changes in their control 3–6 months after the initial intervention and, last but not least, the selection of patients with suspected familial hypercholesterolemia (FH). The methodology and basic characteristics have already been mentioned in the previous article, so it will not be discussed further. The aim of this paper is to evaluate the change in control of AH/DLP and to analyze in detail the pharmacotherapy of the population and to discuss the obtained data. The results of the presented study show that even in the short term more satisfactory controls of AH/DLP can be achieved, almost doubling the percentage of patients in which these parameters are controlled. As in the series of EUROASPIRE and LIPIcontrol, for example, we again document a better control of AH, when combination therapy (ACEi + BKK + diuretics) is correctly selected, while DLP is properly treated with modern statins (atorvastatin or rosuvastatin), but unfortunately in rela­tively small doses (10–20mg) and the use of combination therapy to affect LDL-cholesterol levels is rather sporadic, so the percentage of patients with uncontrolled DLP is much higher than with AH. The LipitenCliDec study demonstrates the satisfactory pene­tration of current guidelines into routine clinical practice, when adequate cardioprotective therapy is correctly selected, but this is often titrated with too much caution or omitted with appropriate combination therapy.


cardiovascular risk – arterial hypertension – dyslipidemia – cardiovascular prevention – familial hypercholesterolemia

  1. Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37(42): 3232–3245. Dostupné z DOI: <>. Erratum in Corrigendum to: Cardiovascular disease in Europe: epidemiological update 2016. [Eur Heart J. 2019].
  2. Vrablík M, Piťha J, Bláha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. AtheroRev 2019; 4(3): 126–137.
  3. Widimský J jr, Filipovský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze KV Prevence 2018; 7(Suppl): 3–22. Dostupné z WWW: <>.
  4. Widimský J. Léčba hypertenze v každodenní praxi. Interní Med 2010; 12(5): 236–246.
  5. Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373(9667): 929–940. Dostupné z DOI: <–6736(09)60330–5>.
  6. Šatný M, Tůmová E, Vrablík M at al. Profil pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v primární péči v Česku – studie LipitenCliDec: výsledky 1. fáze. AtheroRev 2020, 5(1): 47–52.
  7. Šatný M, Tůmová E, Vrablík M. LIPIcontrol: daří se zlepšovat úroveň kontroly hlavních rizikových faktorů kardiovaskulárních onemocnění v každodenní praxi?. Hypertenze KV Prevence 2018; 7(1): 15–21.
  8. Šatný M, Vrablík M. Moderní kombinační léčba ke snížení kardiovaskulárního rizika. Practicus 2018, 17(3): 19–23.
  9. Catapano AL, Graham I, De Backer G et al. [ESC Scientific Document Group]. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: <>.
  10. Vrablík M, Laštůvka J, Tůmová E et al. Šest otázek použití ezetimibu v roce 2018. Farmakoterapie 2018; 14(1): 88–93.
  11. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381. Dostupné z DOI: <>.
  12. Vrablík M, Piťha J, Blaha V et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipid­emií z roku 2016. AtheroRev 2017; 2(3): 185–193.
Angiology Diabetology Internal medicine Cardiology General practitioner for adults

Article was published in

Athero Review

Issue 2

2020 Issue 2

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account